AC Immune (ACIU) Current Deferred Revenue (2014 - 2025)

AC Immune (ACIU) has 12 years of Current Deferred Revenue data on file, last reported at $104.7 million in Q4 2025.

• On a quarterly basis, Current Deferred Revenue rose 7.87% year-over-year to $104.7 million in Q4 2025; TTM through Dec 2025 was $104.7 million, a 7.87% increase from a year earlier, with the FY2025 full-year figure at $101.0 million, up 3.98% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $104.7 million, up from $97.1 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for ACIU reached as high as $777.6 million in Q4 2021 and fell as low as $18467.3 in Q3 2024.
• Historically, Current Deferred Revenue has averaged $177.9 million across 5 years, with a median of $97.1 million in 2024.
• Across the five-year window, Current Deferred Revenue surged 229626.92% in 2021 and slumped 99.92% in 2022, its largest moves.
• Year by year, Current Deferred Revenue stood at $777.6 million in 2021, then slumped by 99.92% to $609318.9 in 2022, then jumped by 25432.59% to $155.6 million in 2023, then slumped by 37.59% to $97.1 million in 2024, then rose by 7.87% to $104.7 million in 2025.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $104.7 million in Q4 2025, $97.1 million in Q4 2024, and $18467.3 in Q3 2024.